Table 1.
Frequency of teratoma formation after injection of ESCs or in vitro-differentiated cells in various hosts
| Host | CsA | ESC | Differentiated cells (day 14) |
|---|---|---|---|
| Syngeneic (129Sv, H2b) | – | 96% (25/26) | 95% (21/22) |
| Allogeneic (C57BL/6, H2b) | – | 0% (0/19) | 0% (0/25) |
| Allogeneic (C3H, H2k) | – | 0% (0/13) | 0% (0/21) |
| Xenogeneic (LOU/c, RT1u) | – | 0% (0/12) | 0% (0/17) |
| Allogeneic SCID/beige (C.B-17, H2d) | – | 93% (13/14) | 94% (17/18) |
| Allogeneic SCID (C.B-17, H2d) | – | 100% (15/15) | Not tested |
| Syngeneic (129Sv, H2b) | + | 94% (15/16) | 83% (10/12) |
| Allogeneic (C57BL/6, H2b) | + | 0% (0/12) | 8% (1/13) |
| Allogeneic (C3H, H2k) | + | 7% (1/15) | 9% (1/11) |
| Xenogeneic (LOU/c, RT1u) | + | 0% (0/25) | 61% (11/18) |
MPI-II ESCs and cells differentiated in vitro for 14 days on PA6 feeder cells (>95% neuronal cells) were injected subcutaneously into the flank of syngeneic or allogeneic mice or xenogeneic rats (1 × 106 cells/animal). Some recipients received an immunosuppressive treatment with CsA (10 mg/kg/day). The percentage and number of animals in which tumors were found during autopsy or in which tumors were palpable (at least during three consecutive observations) at the side of injection before day 100 after injection is indicated. The table is modified from [61]
CsA cyclosprin, ESC embryonic stem cell